225 related articles for article (PubMed ID: 31593878)
1. Differential redox-regulation and mitochondrial dynamics in normal and leukemic hematopoietic stem cells: A potential window for leukemia therapy.
Mattes K; Vellenga E; Schepers H
Crit Rev Oncol Hematol; 2019 Dec; 144():102814. PubMed ID: 31593878
[TBL] [Abstract][Full Text] [Related]
2. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
[TBL] [Abstract][Full Text] [Related]
3. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
Li Y; Chen K; Zhou Y; Xiao Y; Deng M; Jiang Z; Ye W; Wang X; Wei X; Li J; Liang J; Zheng Z; Yao Y; Wang W; Li P; Xu B
Curr Cancer Drug Targets; 2015; 15(6):493-503. PubMed ID: 26282548
[TBL] [Abstract][Full Text] [Related]
4. Mitochondria: A Galaxy in the Hematopoietic and Leukemic Stem Cell Universe.
Panuzzo C; Jovanovski A; Pergolizzi B; Pironi L; Stanga S; Fava C; Cilloni D
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486249
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches.
Hira VVV; Van Noorden CJF; Carraway HE; Maciejewski JP; Molenaar RJ
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):183-198. PubMed ID: 28363872
[TBL] [Abstract][Full Text] [Related]
6. [Progress in the studies of acute myelogenous leukemia stem cell].
Cui JW; Zhang XM; Wang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Oct; 11(5):549-52. PubMed ID: 14575558
[TBL] [Abstract][Full Text] [Related]
7. [Progress in the leukemic stem cell study and a novel therapeutic approach targeting leukemic stem cells].
Kikushige Y; Miyamoto T; Akashi K
Rinsho Ketsueki; 2017; 58(10):1838-1843. PubMed ID: 28978822
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities.
O'Reilly E; Zeinabad HA; Szegezdi E
Blood Rev; 2021 Nov; 50():100850. PubMed ID: 34049731
[TBL] [Abstract][Full Text] [Related]
9. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
Kikushige Y; Miyamoto T
Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
[TBL] [Abstract][Full Text] [Related]
10. Targeting mitochondrial respiration for the treatment of acute myeloid leukemia.
Carter JL; Hege K; Kalpage HA; Edwards H; Hüttemann M; Taub JW; Ge Y
Biochem Pharmacol; 2020 Dec; 182():114253. PubMed ID: 33011159
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
[TBL] [Abstract][Full Text] [Related]
12. [Acute myeloid leukemia stem cells from genomic and immunological perspectives].
Goyama S
Rinsho Ketsueki; 2020; 61(9):1130-1137. PubMed ID: 33162508
[TBL] [Abstract][Full Text] [Related]
13. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
Pelosi E; Castelli G; Testa U
Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
[TBL] [Abstract][Full Text] [Related]
14. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
[TBL] [Abstract][Full Text] [Related]
15. Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.
Di Marcantonio D; Martinez E; Sidoli S; Vadaketh J; Nieborowska-Skorska M; Gupta A; Meadows JM; Ferraro F; Masselli E; Challen GA; Milsom MD; Scholl C; Fröhling S; Balachandran S; Skorski T; Garcia BA; Mirandola P; Gobbi G; Garzon R; Vitale M; Sykes SM
Clin Cancer Res; 2018 Feb; 24(3):608-618. PubMed ID: 29127121
[No Abstract] [Full Text] [Related]
16. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
[TBL] [Abstract][Full Text] [Related]
17. Oxidative resistance of leukemic stem cells and oxidative damage to hematopoietic stem cells under pro-oxidative therapy.
Chen Y; Liang Y; Luo X; Hu Q
Cell Death Dis; 2020 Apr; 11(4):291. PubMed ID: 32341354
[TBL] [Abstract][Full Text] [Related]
18. Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells.
Reinisch A; Chan SM; Thomas D; Majeti R
Semin Hematol; 2015 Jul; 52(3):150-64. PubMed ID: 26111462
[TBL] [Abstract][Full Text] [Related]
19. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K
Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
